Is OncoCyte Corp. overvalued or undervalued?

As of 24 March 2025, the valuation grade for OncoCyte Corp. has moved from does not qualify to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued given its high Price to Book Value of 8.31, a negative EV to EBIT of -2.37, and an EV to Sales ratio of 14.39, which suggests that the market is pricing the stock at a premium despite its losses. In comparison to its peer, Cyclo Therapeutics, Inc., which has an EV to EBITDA of -1.3007, OncoCyte's metrics indicate a less favorable position. Additionally, the company's recent stock performance shows a 41.60% year-to-date return, significantly outperforming the S&P 500's 12.22%, but this is overshadowed by a drastic decline of 87.96% over the past five years, highlighting the volatility and risk associated with the stock.